Oxidized LDL, anti-oxidized LDL and anti-annexin A5 antibodies in primary antiphospholipid syndrome

Clinical Laboratory

Volumn 54, Issue 3-4, 2008, Pages 97-101

  Becarevic, Mirjana ^a   Singh, Sandra ^a   Majkic Singh, Nada ^a,b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b Pharmaceutical Faculty   (Serbia)

Author keywords

Anti annexin A5 antibodies; Anti oxidized LDL antibodies; Myocardial infarction; Oxidized LDL; Primary antiphospholipid syndrome; Pulmonary emboli

Indexed keywords

IMMUNOGLOBULIN G; LIPOCORTIN 5 ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; PROTEIN ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MALE; PATHOPHYSIOLOGY; RECURRENT ABORTION; RISK ASSESSMENT; RISK FACTOR;

ABORTION, HABITUAL; ADULT; ANNEXIN A5; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PULMONARY EMBOLISM;

EID: 46849098189     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Gromnica-Ihle E, Schössler W. Antiphospholipid syndrome. Int Arch Immunol 2000; 123: 67-76.
2. Wilson WA, Gharavi AE, Koike T, et al. International statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an International Workshop. Arthritis Rheum 1999; 42(7): 1309-1311.
3. Miyakis S, Lockshin M, Atsumi T,et al. International Consensus Statement on an update of the classification criteria for the definite antiphospholipid syndrome. J Throm Haemostasis 2006; 4 (2): 295-306.
4. Karvonen J, Paivansalo M, Kesaniemi YA, Horkko S. Immunoglobulin M type of autoantibodies to oxidized lowdensity lipoprotein has an inverse relation to carotid atherosclerosis. Circulation 2003; 108: 2107-2112.
5. Hulthe J, Wiklund O, Hurt-Camejo E, Bondjers G. Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A2. Arterioscler Thromb Vasc Biol 2001: 21; 269-274.
6. Su J, Georgiades A, Wu R, Thulin T, de Faire U, Frostegard J. Antibodies of IgM subclass to phosphorylcholin and oxidized LDL are protective factors in patients with hypertension. Atherosclerosis 2006; 188 (1): 160-166.
7. Bećarević M, Andrejević S, Bonači-Nikolić B, Obradović I, Miljić P, Majkić-Singh N. Anti-oxLDL antibodies - marker for arterial thromboses in antiphospholipid syndrome? Clin Lab 2005; 51: 279 83.
8. Bećarević M, Mirković D, Miljić P, et al. Anti-oxLDL antibodies, homocysteine and apolipoproteins in primary antiphospholipid syndrome. Jugoslov Med Biohem 2006; 25 (2): 167-172.
9. Puurunen M, Mänttäri M, Manninen V, et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2605-2609.
10. Rand JH. Molecular pathogenesis of the antiphospholipid syndrome. Circ Res 2002; 11: 29-37.
11. Rand JH, Wu XX, Quinn AS, et al. Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay. Am J Pathol 2003; 163: 1193-1200.
12. Song GJ, Campos B, Wagoner LE, Dedman JR, Walsh RA. Altered cardiac annexin mRNA and protein levels in the left ventricle of patients with end-stage heart failure. J Moll Cell Cardiol 1998; 30: 443-451.
13. Benevolensky D, Belikova Y, Mohammadzadeh R, et al. Expression and localization of the annexins II, V and VI in myocardium from patients with end-stage heart failure. Lab Invest 2000; 80: 123-133.
14. Brandt JT, Triplett DA, Alving B, Scharrer J. Criteria for the Diagnosis of Lupus Anticoagulans: An Update on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipd Antibody of the Scientific and Standardisation Committee of the International Society of Thrombosis and Haemostasis. Thrombosis Haemostasis 1995; 74 (4): 1185-1190.
15. Shoji T, Nishizava Y, Fukumoto M, et al. Inverse relationship between circulating oxidized low-density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000; 148: 171-177.
16. Brizzi P, Tonolo G, Bertrand G, et al. Autoantibodies against oxidized low-density lipoprotein (ox-LDL) and LDL oxidation status. Clin Chem Lab Med 2004; 42(2): 164-170.
17. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatevely modified LDL in 50-year old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 3159-3163.
18. Rodriguez-Garcia MI, Fernandez JA, Rodriguez A, Fernandez MP, Gutierrez C, Torre-Alonso JC. Annexin V autoantibodies in rheumatoid arthritis. Ann Rheum Dis 1996; 55: 895-900.
19. Ogawa H, Zhao D, Dlott JS, et al. Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities. Am J Clin Pathol 2000; 114: 619-628.
20. De Laat B, Derksen RHWM, Mackie IJ, et al. Annexin A5 polimorphism (-1C>T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 2006; doi:10.1136/ ard.2005.045237.
21. Bizzaro N, Antico A, Musso M, et al. A prospective study of 1038 pregnancies on the predictive value of anti-annexin V antibodies for fetal loss. Ann NY Acad Sci 2005; 248-256.
22. Rand JH, Wu XX, Guller S, et al. Reduction of annexin V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortions. Am J Obstet Gynecol 1994; 171: 1566-1572.
23. Lakasing L, Campa JS, Poston R, Khamashta MA, Poston L. Normal expression of tissue factor, thrombomodulin and annexin V in placentas from women with antiphospholipid syndrome. Am J Obstet Gynecol 1999; 181: 180-189.